FORMA Therapeutics, Inc.
500 Arsenal Street
107 articles with FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. today announced that new data related to FT-4101, its novel, small molecule fatty acid synthase (FASN) inhibitor, in clinical development for the treatment of nonalcoholic steatohepatitis (NASH), will be presented at The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place November 8-12, 2019 in Boston, MA.
9/27/2019Biotech and pharma companies strengthen their leadership teams and boards of directors with this week's appointments.
The Company also announced the appointments of Scott Boyle, Ph.D. as Vice President, Business and Corporate Development and Brian Lesser as Vice President, Therapeutic Head.
FORMA Therapeutics Announces Data for IDH1m Inhibitor Olutasidenib in Glioma to Be Presented at the 2019 Society for NeuroOncology Annual Meeting
Data to highlight the penetration of olutasidenib across the blood brain barrier and preliminary safety and clinical activity from an ongoing Phase 1b/2 study
3/22/2019Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.
FORMA Therapeutics announced today the appointment of Frank D. Lee as Chief Executive Officer, starting on March 27, 2019.
According to WARN notices, the two companies will slash a total of 106 jobs starting in March.
FORMA expands external discovery research footprint with dedicated unit at HitGen
FORMA Therapeutics Announces Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
FT-2102 IDH1m Inhibitor Clinical Data Selected for Oral Presentation
FORMA Therapeutics and the University of Oxford Announce Multi-Year Collaboration to Advance the Development of Deubiquitinating Enzyme (DUB) Inhibitors for the Treatment of Neurodegenerative Diseases
FORMA expands translational footprint in Neurodegeneration with ARUK Oxford Drug Discovery Institute
FORMA Therapeutics (FORMA) today announced the appointment of Tim Clackson, Ph.D., former President, Research and Development, ARIAD Pharmaceuticals, Inc. to the company’s Board of Directors.
FORMA Therapeutics Achieves Key Objective in Collaboration with Celgene Corporation to Advance a Novel Protein Homeostasis Oncology/Immuno-Oncology Program
his collaboration enables Celgene to evaluate select therapeutic candidates and programs in protein homeostasis during preclinical development.
Frances brings more than 30 years of pharmaceutical and regulatory experience, having previously worked for several global and emerging pharmaceutical companies.
FORMA Therapeutics Collaborates with Arpeggio Biosciences to Explore Translational Utility of Drug Candidates
Arpeggio Biosciences will use its proprietary technology to identify immediate biological and genetic changes promoted by specific drug-target interactions
Chris joins the executive leadership team of FORMA with over 20 years of global experience in legal strategy, corporate partnerships and intellectual property, within the public and private Life Sciences sectors.
FORMA Delivers Two Key Objectives In Collaboration With Celgene To Advance Protein Homeostasis Medicines To Benefit Patients
FORMA Announces Achievement Of First Clinical Development Milestone In Partnership With Boehringer Ingelheim